Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets
New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development…
Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage…
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
